التفاصيل البيبلوغرافية
| العنوان: |
Anti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance. |
| المؤلفون: |
Harrington J; Department of Medicine, Division of Cardiology Duke University, Durham, NC (J.H.).; Duke Clinical Research Institute, Durham, NC (J.H.)., Gale SE; Department of Pharmacy Sciences, Atrium Health Carolinas Medical Center, Charlotte, NC (S.E.G.)., Vest AR; Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Kaufman Center for Heart Failure Treatment and Recovery, Cleveland Clinic, OH (A.R.V.). |
| المصدر: |
Circulation. Heart failure [Circ Heart Fail] 2024 Aug 01, pp. e011518. Date of Electronic Publication: 2024 Aug 01. |
| Publication Model: |
Ahead of Print |
| نوع المنشور: |
Journal Article; Review |
| اللغة: |
English |
| بيانات الدورية: |
Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 101479941 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-3297 (Electronic) Linking ISSN: 19413289 NLM ISO Abbreviation: Circ Heart Fail Subsets: MEDLINE |
| أسماء مطبوعة: |
Original Publication: Hagerstown, MD : Lippincott Williams & Wilkins |
| مستخلص: |
Obesity is a significant risk factor for heart failure (HF) development, particularly HF with preserved ejection fraction and as a result, many patients with HF also have obesity. There is growing clinical interest in optimizing strategies for the management of obesity in patients with HF across the spectrums of both ejection fraction and disease severity. The emergence of anti-obesity medications with cardiovascular outcomes benefits, principally glucagon-like peptide-1 receptor agonists, has made it possible to study the impact of anti-obesity medications for patients with baseline cardiovascular conditions, including HF. However, clinical trials data supporting the safety and efficacy of treating obesity in patients with HF is currently limited to patients with HF with preserved ejection fraction, but do confirm safety and weight loss efficacy in this patient population as well as improvements in HF functional status, biomarkers of inflammation and HF stability. Here, we review the current data available surrounding the management of obesity for patients with HF, including the limitations of this evidence and ongoing areas for investigation, summarize the next phase of emerging anti-obesity medications and provide practical clinical advice for the multidisciplinary management of patients with both HF and obesity. |
| فهرسة مساهمة: |
Keywords: cardiovascular diseases; heart failure; obesity; stroke volume; weight loss |
| تواريخ الأحداث: |
Date Created: 20240801 Latest Revision: 20240801 |
| رمز التحديث: |
20240801 |
| DOI: |
10.1161/CIRCHEARTFAILURE.124.011518 |
| PMID: |
39087359 |
| قاعدة البيانات: |
MEDLINE |
Full Text Finder